The demand for Anti-Rheumatic Drugs in D-A-CH has been steadily increasing over the years due to various factors.
Customer preferences: Patients suffering from rheumatoid arthritis and other related illnesses are the primary customers of Anti-Rheumatic Drugs. The preference for these drugs has been increasing due to their effectiveness in managing symptoms and improving the quality of life of patients. Additionally, the growing awareness about the benefits of early diagnosis and treatment has led to an increase in demand for these drugs.
Trends in the market: The Anti-Rheumatic Drugs market in D-A-CH is witnessing a trend towards the development of biologic drugs. These drugs are highly effective and target specific components of the immune system responsible for inflammation. They are also associated with fewer side effects compared to traditional drugs. The market is also seeing an increase in the use of biosimilars, which are cheaper versions of biologic drugs. This trend is driven by the need to reduce healthcare costs while still providing effective treatment options to patients.
Local special circumstances: Germany is the largest market for Anti-Rheumatic Drugs in D-A-CH, and it is also home to some of the leading pharmaceutical companies in the world. This has led to a highly competitive market with a wide range of products available to patients. Switzerland, on the other hand, has a smaller market size but is known for its high-quality healthcare system, which ensures that patients have access to the latest treatment options. Austria has a smaller market size compared to the other two countries but has a growing elderly population, which is a key demographic for Anti-Rheumatic Drugs.
Underlying macroeconomic factors: The increasing prevalence of rheumatoid arthritis and related illnesses is a key macroeconomic factor driving the growth of the Anti-Rheumatic Drugs market in D-A-CH. Additionally, the aging population in these countries is also contributing to the growth of the market. The availability of healthcare insurance and the high level of healthcare spending in these countries are also factors that are driving the growth of the market. Finally, the presence of leading pharmaceutical companies in Germany is also contributing to the growth of the market by driving innovation and competition.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
